273 related articles for article (PubMed ID: 25193361)
1. Dabigatran and warfarin for secondary prevention of stroke in atrial fibrillation patients: a nationwide cohort study.
Larsen TB; Rasmussen LH; Gorst-Rasmussen A; Skjøth F; Lane DA; Lip GY
Am J Med; 2014 Dec; 127(12):1172-8.e5. PubMed ID: 25193361
[TBL] [Abstract][Full Text] [Related]
2. Bleeding rates in Veterans Affairs patients with atrial fibrillation who switch from warfarin to dabigatran.
Vaughan Sarrazin MS; Jones M; Mazur A; Chrischilles E; Cram P
Am J Med; 2014 Dec; 127(12):1179-85. PubMed ID: 25107386
[TBL] [Abstract][Full Text] [Related]
3. Novel Oral Anticoagulant Use Among Patients With Atrial Fibrillation Hospitalized With Ischemic Stroke or Transient Ischemic Attack.
Patel PA; Zhao X; Fonarow GC; Lytle BL; Smith EE; Xian Y; Bhatt DL; Peterson ED; Schwamm LH; Hernandez AF
Circ Cardiovasc Qual Outcomes; 2015 Jul; 8(4):383-92. PubMed ID: 26058721
[TBL] [Abstract][Full Text] [Related]
4. [Effectiveness, safety and costs of stroke prevention in non-valvular auricular fibrillation. Study of cohorts matched by Propensity score].
Giner-Soriano M; Casajuana M; Roso-Llorach A; Vedia C; Morros R
Aten Primaria; 2020 Mar; 52(3):176-184. PubMed ID: 31551166
[TBL] [Abstract][Full Text] [Related]
5. Dabigatran in secondary stroke prevention: clinical experience with 106 patients.
DeFelipe-Mimbrera A; Alonso Cánovas A; Guillán M; Matute C; Sainz de la Maza S; Cruz A; Vera R; Masjuan J
Biomed Res Int; 2014; 2014():567026. PubMed ID: 25133166
[TBL] [Abstract][Full Text] [Related]
6. Risk of stroke and transient ischaemic attack in patients with a diagnosis of resolved atrial fibrillation: retrospective cohort studies.
Adderley NJ; Nirantharakumar K; Marshall T
BMJ; 2018 May; 361():k1717. PubMed ID: 29743285
[TBL] [Abstract][Full Text] [Related]
7. Trends in the Use of Medications for Secondary Ischemic Stroke Prevention in Denmark, 2005-2021.
Skajaa N; Laugesen K; Lauffenburger JC; Schwamm LH; Sørensen HT; Patorno E
Neurology; 2024 May; 102(9):e209309. PubMed ID: 38648572
[TBL] [Abstract][Full Text] [Related]
8. New oral anticoagulants.
Perry TL; Wright JM; Mintzes B; O'Sullivan C; Tejani AM
CMAJ; 2015 May; 187(8):603. PubMed ID: 25991854
[No Abstract] [Full Text] [Related]
9. Secondary stroke: new horizons in prevention.
Phillips RA
Clin Cardiol; 2004 May; 27(5 Suppl 2):II1-3. PubMed ID: 15188930
[No Abstract] [Full Text] [Related]
10. Influenza Vaccination and Ischemic Stroke Prevention: Two for the Price of One.
Yang D; Elkind MSV
Neurology; 2022 Nov; 99(19):827-828. PubMed ID: 36240092
[No Abstract] [Full Text] [Related]
11. Transient new-onset atrial fibrillation during acute coronary syndrome: Transient arrhythmia, transient risk?
López-Palop R; Carrillo P; Lozano Í
Int J Cardiol; 2024 May; 410():132163. PubMed ID: 38754582
[No Abstract] [Full Text] [Related]
12. Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation.
Graham DJ; Reichman ME; Wernecke M; Zhang R; Southworth MR; Levenson M; Sheu TC; Mott K; Goulding MR; Houstoun M; MaCurdy TE; Worrall C; Kelman JA
Circulation; 2015 Jan; 131(2):157-64. PubMed ID: 25359164
[TBL] [Abstract][Full Text] [Related]
13. Ischemic stroke and intracranial hemorrhage with aspirin, dabigatran, and warfarin: impact of quality of anticoagulation control.
Ho CW; Ho MH; Chan PH; Hai JJ; Cheung E; Yeung CY; Lau KK; Chan KH; Lau CP; Lip GY; Leung GK; Tse HF; Siu CW
Stroke; 2015 Jan; 46(1):23-30. PubMed ID: 25406148
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness and safety of dabigatran and warfarin in real-world US patients with non-valvular atrial fibrillation: a retrospective cohort study.
Lauffenburger JC; Farley JF; Gehi AK; Rhoney DH; Brookhart MA; Fang G
J Am Heart Assoc; 2015 Apr; 4(4):. PubMed ID: 25862791
[TBL] [Abstract][Full Text] [Related]
15. Risk of bleeding with dabigatran in atrial fibrillation.
Hernandez I; Baik SH; Piñera A; Zhang Y
JAMA Intern Med; 2015 Jan; 175(1):18-24. PubMed ID: 25365537
[TBL] [Abstract][Full Text] [Related]
16. Non-vitamin K antagonist oral anticoagulation agents in anticoagulant naïve atrial fibrillation patients: Danish nationwide descriptive data 2011-2013.
Olesen JB; Sørensen R; Hansen ML; Lamberts M; Weeke P; Mikkelsen AP; Køber L; Gislason GH; Torp-Pedersen C; Fosbøl EL
Europace; 2015 Feb; 17(2):187-93. PubMed ID: 25236181
[TBL] [Abstract][Full Text] [Related]
17. Dabigatran adherence in atrial fibrillation patients during the first year after diagnosis: a nationwide cohort study.
Gorst-Rasmussen A; Skjøth F; Larsen TB; Rasmussen LH; Lip GY; Lane DA
J Thromb Haemost; 2015 Apr; 13(4):495-504. PubMed ID: 25594442
[TBL] [Abstract][Full Text] [Related]
18. Vitamin K antagonist-experienced patients with a history of stroke/transient ischaemic attack who switched from warfarin to dabigatran increased their rate of recurrent stroke/transient ischaemic attack compared with those on warfarin.
Eikelboom JW; Bosch J
Evid Based Med; 2015 Jun; 20(3):117. PubMed ID: 25870161
[No Abstract] [Full Text] [Related]
19. Safety and effectiveness of dabigatran and warfarin in routine care of patients with atrial fibrillation.
Seeger JD; Bykov K; Bartels DB; Huybrechts K; Zint K; Schneeweiss S
Thromb Haemost; 2015 Nov; 114(6):1277-89. PubMed ID: 26446507
[TBL] [Abstract][Full Text] [Related]
20. Management and clinical outcomes in patients treated with apixaban vs warfarin undergoing procedures.
Garcia D; Alexander JH; Wallentin L; Wojdyla DM; Thomas L; Hanna M; Al-Khatib SM; Dorian P; Ansell J; Commerford P; Flaker G; Lanas F; Vinereanu D; Xavier D; Hylek EM; Held C; Verheugt FW; Granger CB; Lopes RD
Blood; 2014 Dec; 124(25):3692-8. PubMed ID: 25320240
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
